REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

NCT06826677 | Completed

• 1 other identifier: D9070R00001
• Study Type: observational
• Target: 71
• Locations: 1 country
• Sites: 11

Brief Summary

Primary lung cancer is one of the most common malignancies and causes of cancer-related death worldwide \[Passiglia et al., 2019; Bade and Dela Cruz, 2020\]. Lung cancer is classified into different types, among which small cell lung cancer (SCLC), accounting for 13%-20% of all lung cancer cases \[Pezzuto et al., 2019; Torres-Durán et al., 2021\], is an aggressive form of neuroendocrine malignancy characterized by rapid growth, tendency to disseminate early and high relapse rates \[El Sayed and Blais, 2021\]. There are persistently limited treatment options for SCLC \[DiBonaventura et al., 2019; El Sayed and Blais, 2021\], and the current clinical approach to SCLC treatment is chosen irrespective of biological subtype \[Rudin et al., 2021; Keogh et al., 2022\]. First-line treatments for ES-SCLC have been platinum-based chemotherapy combinations for decades, without significant differences in Overall Survival (OS) between cisplatin and carboplatin, valuing flexibility in the choice of platinum agent in treatment decision making for individual patients \[Dingemans et al., 2021\]. However, despite the high initial response rate, the prognosis remains poor \[Zhang et al., 2021; Johal et al., 2021\]. In recent years, immunotherapy has dramatically modified cancer treatment across several malignancies and has been an active area of investigation in SCLC \[Calles et al., 2019; Dingemans et al., 2021\]. Treatments that combine chemotherapy and immune checkpoint inhibitors (ICIs), such as durvalumab and atezolizumab, can increase immune responses to tumor cells, resulting in improved efficacy in ES-SCLC compared to chemotherapy alone \[Esposito et al., 2020; Konala et al., 2020; Hiddinga et al., 2021; Lim and Kang, 2021\]. These treatment regimens have been approved in many countries \[Wang et al., 2022\] and are now the standard of care in the ES-SCLC first-line setting, according to the ESMO \[Dingemans et al., 2021\] and the NCCN Clinical Practice Guidelines in Oncology \[Ganti et al., 2022\]. Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of programmed cell death ligand-1 (PD-L1) with PD-1 and CD80 \[IMFINZI® (durvalumab) Summary of Product Characteristics\]. The phase III CASPIAN study (ClinicalTrials.gov identifier: NCT03043872) showed that the addition of durvalumab to a combination regimen of etoposide with either cisplatin or carboplatin significantly improved OS compared with etoposide and platinum alone, with a manageable tolerability profile \[Paz-Ares et al., 2019; Goldman et al., 2021; Paz-Ares et al., 2022\]. Following the CASPIAN study, an Early Access Programme (EAP) to provide pre-approval access to durvalumab plus platinum-etoposide for ES-SCLC patients eligible to receive first-line platinum-based chemotherapy (D419QR00007 EAP, hereafter called 'CASPIAN EAP') was activated in Italy in March 2020, including 125 subjects across 39 oncology centers. Clinical trials have demonstrated significant efficacy and a favorable safety profile of durvalumab combined with chemotherapy in ES-SCLC \[Paz-Ares et al., 2022\]. On the other hand, it is estimated that stringent eligibility criteria may exclude up to 70% of patients with lung cancer from ICI clinical trials \[von Itzstein et al., 2020\]. Understanding the efficacy and safety of ICIs in a more heterogeneous patient population than in randomized controlled trials is critical to realizing the full potential of these therapies. To fill the gap between strictly controlled clinical trial populations and actual lung cancer patients managed in clinical practice, observational studies from real-world settings are emerging \[von Itzstein et al., 2020\]. Although real-world studies are unable to achieve the high internal validity of randomized controlled trials (RCTs), accurately performed analyses of real-world data can provide valuable complementary results \[Nazha et al., 2021\]. In conclusion, considering that ES-SCLC are often elderly patients with multiple comorbidities \[Schulkes et al., 2016\] for whom the treatment decision-making is challenging \[DiBonaventura et al., 2019\], the ARAL observational study will contribute to filling the information gap by collecting real-world data from the CASPIAN EAP to better describe durvalumab treatment outcomes and treatment patterns among patients diagnosed with ES-SCLC in Italy.

Conditions

Small Cell Lung Carcinoma

Outcome Measures

Primary Outcomes (3)

• Overall survival

  OS rate at 12 and 18 months after index date (defined as Day 1 of Cycle 1 - C1 D1 of platinum-etoposide chemotherapy)

  12 and 18 months after index date

• Overall survival

  Median OS

  From index date to death or date of enrollment in the study (up to 5 years)

• Overall Survival

  Mean OS

  From index date to death or date of enrollment in the study (up to 5 years)

Secondary Outcomes (18)

• Overall Survival

  24 months after index date

• Progression Free Survival

  12, 18, 24 months after index date

• Progression free survival

  From index date to death or progression or date of enrollment in the study (up to 5 years)

• Time to discontinuation

  From index date to last dose of treatment with durvalumab or death or date of enrollment in the study (up to 5 years)

• Time to First Subsequent Therapy or Death

  From index date to start of other cancer treatment or death or date of enrollment in the study (up to 5 years)

Other Outcomes (3)

• Time interval from initial diagnosis of SCLC to test execution (e.g. biomarker test, gene mutational test,histological/cytological test)

  from SCLC diagnosis to test execution (up to 3 monts)

• Time interval from diagnosis of extended disease to test execution (e.g. biomarker test, gene mutational test,histological/cytological confirmation)

  from diagnosis of extended disease to test execution (up to 3 monts)

• RR

  from index date until disease progression or the last evaluable assessment (up to 5 years)

Interventions

Durvalumab DRUG

PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study is focused on studying a cohort of adult patients diagnosed with ES-SCLC, treated with durvalumab in combination with platinum (cisplatin or carboplatin) and etoposide as first-line therapy in the context of the CASPIAN EAP implemented in Italy. Approximately 90 subjects are expected to be included across about 15 sites in Italy, during an expected inclusion period of about 8 months.

You may qualify if:

• Patients with diagnosis of extensive-stage Small Cell Lung Cancer (ES-SCLC).
• Patients having performed at least one administration of durvalumab treatment in the CASPIAN EAP.
• Patients (or their legally acceptable representatives) who have signed the subject informed consent and privacy form, if applicable.

You may not qualify if:

• \. Patients with unavailable medical chart.

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (11)

Research Site

Bologna, Italy

Location

Research Site

Catanzaro, Italy

Location

Research Site

Lucca, Italy

Location

Research Site

Napoli, Italy

Location

Research Site

Palermo, Italy

Location

Research Site

Pistoia, Italy

Location

Research Site

Prato, Italy

Location

Research Site

Roma, Italy

Location

Research Site

Trento, Italy

Location

Research Site

Varese, Italy

Location

Research Site

Vimercate, Italy

Location

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Interventions

durvalumab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2025
• First Posted: February 14, 2025
• Study Start: July 30, 2024
• Primary Completion: January 23, 2025
• Study Completion: January 23, 2025
• Last Updated: June 24, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Locations

IT (11)